Agenus Analyst Ratings
B. Riley Adjusts Price Target on Agenus to $18 From $42, Maintains Buy Rating
B.Riley Financial Maintains Agenus(AGEN.US) With Buy Rating, Cuts Target Price to $18
Agenus Downgraded at Baird After FDA Feedback on Cancer Drug
HC Wainwright Downgrades Agenus to Neutral From Buy, Adjusts Price Target to $9 From $40
HC Wainwright & Co. Downgrades Agenus to Neutral, Lowers Price Target to $9
Agenus Analyst Ratings
Agenus Analyst Ratings
Buy Rating Affirmed for Agenus Amid Promising Colorectal Cancer Study Results
Agenus Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Agenus (AGEN), Merus (MRUS) and Iovance Biotherapeutics (IOVA)
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), Eledon Pharmaceuticals (ELDN) and Agenus (AGEN)
Agenus Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA), Repligen (RGEN) and Agenus (AGEN)
Agenus Shares Target Cut to $5, Analyst Maintains Buy Rating
Agenus Analyst Ratings
B. Riley Securities Trims Agenus' Price Target to $5 From $6 After Model Update, Maintains Buy Rating
Agenus Analyst Ratings
Agenus's Promising Botensilimab Leads to Buy Rating From Analyst Mayank Mamtani
Analysts Are Bullish on Top Healthcare Stocks: Agenus (AGEN), Zivo Bioscience (ZIVO)